03:21 PM EST - IntelGenx Corp. : And RedHill Biopharma Ltd. today announced the signing of an exclusive license agreement with Pharmatronic Co. for the commercialization of RIZAPORT® in the Republic of Korea (South Korea). RIZAPORT® is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. IntelGenx Corp.
shares V.IGX are trading up $0.03 at $0.10.
